Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) Stock Now Rated “Buy” by Sell-Side Brokerages

Shares of Lumexa Imaging Holdings, Inc. (NASDAQ:LMRI) have received a consensus rating of “Buy” from the six research firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have given a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $16.40.

Several research firms have recently issued reports on LMRI. Deutsche Bank Aktiengesellschaft set a $16.00 target price on shares of Lumexa Imaging in a research note on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Lumexa Imaging in a research note on Tuesday, September 22nd. Raymond James Financial set a $17.00 price objective on shares of Lumexa Imaging in a report on Monday, September 28th. UBS Group reissued a “strong-buy” rating on shares of Lumexa Imaging in a research note on Monday, September 28th. Finally, Barclays upped their price target on shares of Lumexa Imaging from $9.00 to $13.00 and gave the stock an “overweight” rating in a research report on Friday, August 28th.

Lumexa Imaging Stock Up 0.9%

NASDAQ:LMRI opened at $11.73 on Friday. The company has a debt-to-equity ratio of 1.40, a current ratio of 1.44 and a quick ratio of 1.44. Lumexa Imaging has a 1-year low of $6.45 and a 1-year high of $19.45. The company has a 50-day moving average of $11.11 and a 200 day moving average of $11.11. The firm has a market cap of $1.13 billion and a PE ratio of -23.94.

Lumexa Imaging (NASDAQ:LMRI) last announced its earnings results on Wednesday, August 12th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.17. The firm had revenue of $264.16 million during the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. As a group, research analysts anticipate that Lumexa Imaging will post 0.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Lumexa Imaging

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Strs Ohio purchased a new stake in Lumexa Imaging during the first quarter worth about $38,000. State of Alaska Department of Revenue acquired a new position in Lumexa Imaging in the third quarter valued at approximately $46,000. PNC Financial Services Group Inc. acquired a new stake in shares of Lumexa Imaging during the first quarter worth about $63,000. State of Wyoming purchased a new stake in Lumexa Imaging in the 1st quarter valued at $91,000. Finally, AXQ Capital LP purchased a new stake in Lumexa Imaging during the 2nd quarter valued at approximately $128,000.

About Lumexa Imaging

Lumexa Imaging is a U.S.-based provider of outpatient diagnostic imaging and radiology services. The company operates imaging centers and offers services designed to support physicians, hospitals, health systems and patients in the diagnosis and monitoring of medical conditions.

Its service portfolio includes advanced imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound and X-ray. Lumexa also provides radiology-related services, including image interpretation and support for referring healthcare providers, through fixed-site and mobile imaging operations.

The company serves communities across the United States through its network of outpatient facilities and healthcare partnerships.